Design, synthesis, and inhibition of oxidative, amyloidogenic, and cholinergic dysfunction of saxagliptin-derived schiff bases against STZ-induced sporadic AD-like pathology

This publication has 32 references indexed in Scilit:

• Plumbagin as a potential therapeutic agent for scopolamine-induced Alzheimer’s disease: Mechanistic insights into GSK-3β inhibition
  Brain Research, 2025
• Repurposing drugs: promising therapeutic approach against Alzheimer’s disease
  Ageing Research Reviews, 2025
• Exploring DPP IV inhibitors for Alzheimer’s disease: Bridging diabetes and neurodegeneration
  Brain Research, 2024
• Animal model of Alzheimer’s disease induced by streptozotocin: New insights about cholinergic pathway
  Brain Research, 2022
• Bilateral intracerebroventricular injection of streptozotocin induces AD-like behavioral impairments and neuropathological features in mice: Involved with the fundamental role of neuroinflammation
  Biomedicine & Pharmacotherapy, 2022
• Therapeutic efficacy of Clompanus pubescens leaves fractions via downregulation of neuronal cholinesterases/Na+-K+ATPase/IL-1 β, and improving the neurocognitive and antioxidants status of streptozotocin-induced diabetic rats
  Biomedicine & Pharmacotherapy, 2022
• Design and synthesis of novel coumarin derivatives as potential acetylcholinesterase inhibitors for Alzheimer's disease
  Bioorganic Chemistry, 2021
• 7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance
  Psychopharmacology, 2021
• Swertiamarin and quercetin combination ameliorates hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced type 2 diabetes mellitus in wistar rats
  Biomedicine & Pharmacotherapy, 2020
• Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer’s Disease: in Search of a Relevant Mechanism
  Molecular Neurobiology, 2015